Additive Effect of Probiotics (Mutaflor®) in Patients With Ulcerative Colitis on 5-ASA Treatment.

Launched by KANGBUK SAMSUNG HOSPITAL · Jul 16, 2021

Keywords

ClinConnect Summary

This is a multicentre, double-blind, randomised, placebo-controlled study in patients with mild-to-moderate UC.

Subjects were randomly assigned to receive either E.coli Nissle 1917 (Mutaflor®) or placebo once daily for 8 weeks, and inflammatory bowel disease questionnaire (IBDQ) scores, clinical remission, and response rate were compared.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ulcerative colitis patients over the age of 19 with mild to moderate symptoms using 5-ASA (Mayo score 3-9)
• • Patient who signed the consent form
• Exclusion Criteria:
• • The extent of ulcerative colitis is limited to proctitis
• • History of bowel resection
• • History of using other medication than 5-ASA such as immunomodulators, steroid or biologics within 3months
• • history of using antibiotics or probiotics within 2 weeks
• • Pregnant or lactating woman
• • Requiring hospitalization and imminent need for surgery